update desk

Imperva to be acquired by Thoma Bravo for $2.1 billion

California-based cybersecurity software-maker with development centers in Tel Aviv and Rehovot will continue operating as a privately held company.

Israeli children in second grade (7 and 8 years old) use computers in a classroom during a lesson at the "Janusz Korczak" school  in Jerusalem, on May 17, 2011. Photo by Kobi Gideon/Flash90.
Israeli children in second grade (7 and 8 years old) use computers in a classroom during a lesson at the "Janusz Korczak" school in Jerusalem, on May 17, 2011. Photo by Kobi Gideon/Flash90.

Information-security software firm Imperva has entered into a definitive agreement to be acquired by American private-equity technology investment firm Thoma Bravo in a transaction valued at approximately $2.1 billion.

Headquartered in Redwood City, Calif., with development offices in Tel Aviv and Rehovot, Imperva was founded in 2002 as WEBcohort by Israeli cybersecurity experts Shlomo Kramer, Amichai Shulman and Mickey Boodaei.
Imperva will delist from NASDAQ and operate as a privately held company under its current executive team upon the close of the acquisition deal late this year or early next year.

“Thoma Bravo has long admired Imperva’s innovative products and strong market position,” said Seth Boro, a managing partner at Thoma Bravo. “As a leading company that protects data and applications, regardless of whether they live in the cloud, on-premise or in a hybrid environment, Imperva is ahead of the curve from the rest of the cybersecurity industry, and we’re thrilled with this exciting partnership.”

Imperva’s Incapsula, SecureSphere and CounterBreach product lines help organizations protect websites, applications, APIs and databases from cyber attacks while ensuring compliance. It counts 6,200 customers and 500 partners in more than 100 countries.

You have read 3 articles this month.
Register to receive full access to JNS.

Just before you scroll on...

Israel is at war. JNS is combating the stream of misinformation on Israel with real, honest and factual reporting. In order to deliver this in-depth, unbiased coverage of Israel and the Jewish world, we rely on readers like you. The support you provide allows our journalists to deliver the truth, free from bias and hidden agendas. Can we count on your support? Every contribution, big or small, helps JNS.org remain a trusted source of news you can rely on.

Become a part of our mission by donating today
Topics
Comments
Thank you. You are a loyal JNS Reader.
You have read more than 10 articles this month.
Please register for full access to continue reading and post comments.